Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Anti-PD-(L)1 refractory GI cancers

Anti-PD-(L)1 refractory GI cancers

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
FMT + Nivolumab Shows 20% ORR in 10 ICI-Refractory GI Cancer Patients
Oncology Phase I
FMT + Nivolumab Shows 20% ORR in 10 ICI-Refractory GI Cancer Patients Could a gut bacteria transplant help when immunotherapy stops working for stomach cancer?
A phase I study in 10 patients with anti-PD-(L)1-refractory GI cancers found the combination of fecal microbiota transplantation (FMT) and n…
When stomach cancer resists standard immunotherapy, a gut bacteria transplant combined with treatment helped tumors shrink in two patients a…
Mar 30, 2026